🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

103 results for “GlaxoSmithKline” Clear

  1. Bendafolin 10 mg/ml Injektionslösung, Benda-5 FU 50 mg/ml Injektionslösung, Xtandi - 40 mg film-coated tablets, Zirabev 25 mg/ml concentrate for solution for infusion, BENDAFOLIN 10 mg/ml Injektionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, 5-Флуороурацил Ебеве 50 mg/ml концентрат за инжекционен и инфузионен разтвор., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung, Zirabev 25 mg/ml concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Neoplasms

    phase 2 small molecule active

    1 trial

  2. Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen., Benlysta 200 mg solution for injection in pre-filled pen.

    GlaxoSmithKline Biologicals S.A.

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  3. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline Biologicals S.A.

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  4. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline Biologicals S.A.

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  5. CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé, Capecitabine Accord 150 mg film-coated tablets, Oxaliplatin Bendalis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Capecitabin "Zentiva", filmovertrukne tabletter, Capecitabina Zentiva 500 mg compresse rivestite con film., Capecitabine Zentiva 150 mg filmdragerade tabletter, Capecitabin "Zentiva", filmovertrukne tabletter, CAPECITABINE ZENTIVA 150 mg, comprimé pelliculé,

    GlaxoSmithKline Biologicals S.A.

    MMRp/ MSS colon cancer

    phase 2 small molecule active

    1 trial

  6. Carboplatino Hikma 10 mg/ml soluzione per infusione, Avastin 25 mg/ml concentrate for solution for infusion., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Tumours, Gynecological

    phase 2 small molecule active

    1 trial

  7. Dectova 10 mg/mL solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Influenza, Human

    phase 2 small molecule active

    1 trial

  8. Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

    GlaxoSmithKline Biologicals S.A.

    Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

    phase 2 other active

    1 trial

  9. Isatuximab, Dexa-ratiopharm® 8 mg Injektionslösung, Fortecortin® 2 mg Tabletten, Revlimid 15 mg hard capsules, Zelvina 2.5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 2.5 mg hard capsules, Zelvina 5 mg hard capsules, Zelvina 25 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Zelvina 10 mg hard capsules, Revlimid 25 mg hard capsules, Imnovid 1 mg hard capsules, Dexamethason 8 mg GALEN® Tabletten, Nirogacestat, Isatuximab, Nirogacestat, Dexa 8 mg inject JENAPHARM Injekti

    GlaxoSmithKline Biologicals S.A.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  10. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  11. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Relapsed/Refractory Tumors

    phase 2 small molecule active

    1 trial

  12. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Head and Neck

    phase 2 small molecule active

    1 trial

  13. JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Rectal

    phase 2 small molecule active

    1 trial

  14. JEMPERLI 500 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  15. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline Biologicals S.A.

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  16. Locally Sourced 0.9% Sodium Chloride

    GlaxoSmithKline Biologicals S.A.

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  17. NaCl 0.9% solution

    GlaxoSmithKline Biologicals S.A.

    Meningitis, Meningococcal

    phase 2 small molecule active

    1 trial

  18. NaCl solution

    GlaxoSmithKline Biologicals S.A.

    Herpes Simplex

    phase 2 small molecule active

    1 trial

  19. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP

    GlaxoSmithKline Biologicals S.A.

    Infections, Meningococcal

    phase 2 small molecule active

    1 trial

  20. POMALIDOMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, BORTEZOMIB, POMALIDOMIDE, CARFILZOMIB, POMALIDOMIDE, CARFILZOMIB, DEXAMETHASONE

    GlaxoSmithKline Biologicals S.A.

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  21. Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin-Teva 10 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion, JEMPERLI 500 mg concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion.

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  22. Placebo for Bepirovirsen Solution for Injection, 150 mg/mL SSD

    GlaxoSmithKline Biologicals S.A.

    Hepatitis B

    phase 2 small molecule active

    1 trial

  23. Placebo for GSK5784283.

    GlaxoSmithKline Biologicals S.A.

    Asthma

    phase 2 small molecule active

    1 trial

  24. Placebo to Match GSK3915393 Tablet

    GlaxoSmithKline Biologicals S.A.

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources